Home :: Medication :: Infergen

Latest Infergen News

InterMune Announces Fourth Quarter and Year End 2005 Financial ... - PR Newswire (press release)

Table A InterMune, Inc. PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except per share amounts) Three Months Ended Twelve Months Ended December 31 December 31 2005 2004 2005 2004 Revenues Actimmune $27,923 $30,647 $107,313 $124,980 Other products 772 658 2,863 3,700 Total revenues 28,695 31,305 110,176 128,680 Costs and expenses: Cost of goods sold 7,235 7,093 33,842 33,139 Amortization of product rights 125 186 1,180 743 Research and development 18,978 24,740 73,797 74,600 Selling, general and administrative 12,041 16,986 56,638 54,708 Restructuring charges 5,412 -- 5,412 -- Total costs and expenses 43,791 49,005 170,869 163,190 Loss from operations (15,096) (17,700) (60,693) (34,510) Interest income 892 933 3,965 3,490 Interest expense (325) (317) (1,261) (5,065) Other income (expense) 523 (351) 1,313 (7,451) Loss from continuing operations (14,006) (17,435) (56,676) (43,536) Discontinued operations: Loss from discontinued operations (11,437) (4,405) (33,669) (15,942) Gain on sale of discontinued operations (net of taxes and transaction costs) 85,118 -- 85,118 -- Net income (loss) from discontinued operations 73,681 (4,405) 51,449 (15,942) Net income (loss) $59,675 $(21,840) $(5,227) $(59,478) Basic and diluted net income (loss) per share: Continuing operations $(0.43) $(0.54) $(1.76) $(1.37) Discontinued operations $2.27 $(0.14) $1.60 $(0.50) Net income (loss) per share $1.84 - More available

Infergen

No Ebay Marketplace Listings Found